AmitMahipalMD

Oncology • Rochester, MN

Gastrointestinal Cancer

Director, GI oncology; Professor

Join to view full profile

Dr. Mahipal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mahipal's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Fax+1 216-844-5234

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ConnecticutResidency, Internal Medicine, 2005 - 2008
Maulana Azad Medical CollegeClass of 2003, MBBS

Certifications & Licensure

OH State Medical License 2022 - 2026
FL State Medical License 2011 - 2023
MN State Medical License 2016 - 2022
PA State Medical License 2008 - 2012
American Board of Internal Medicine Medical Oncology

Clinical Trials

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects Start of enrollment: 2011 Oct 01
Completed
Phase 1
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Start of enrollment: 2013 Sep 01
Terminated
Phase 1
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Single Agent Regorafenib in Refractory Advanced Biliary Cancers Start of enrollment: 2014 Jun 05
Completed
Phase 2
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Start of enrollment: 2014 May 22
Completed
Phase 1
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer Start of enrollment: 2014 Oct 30
Completed
Phase 1
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer Start of enrollment: 2014 Oct 31
Completed
Phase 1, Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
TAS-102 in Treating Advanced Biliary Tract Cancers Start of enrollment: 2017 Oct 20
Completed
Phase 2
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Start of enrollment: 2019 Oct 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

38 citations
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Zhaohui Jin, Mindy L. Hartgers, Cristobal T. Sanhueza, Christopher R. Shubert, Steven R. Alberts
European Journal of Surgical Oncology. 2018-02-16
21 citations
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
Daniel H. Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, Heidi E. Kosiorek, Thorvardur R. Halfdanarson
Investigational New Drugs. 2021-08-31
7 citations
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer
Olatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology

Authored Content

A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020